-
公开(公告)号：US20210251903A1
公开(公告)日：2021-08-19
申请号：US16791825
申请日：2020-02-14
摘要： The present invention relates to a process for preparation of a water-insoluble steroid composition by moist heat sterilization. Particularly, the invention relates to a process for preparation of a water-insoluble steroid composition comprising moist heat sterilization of an aqueous slurry of the steroid triamcinolone acetonide in the presence of benzyl alcohol, sodium chloride and sodium carboxymethylcellulose under a nitrogen atmosphere. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.
-
公开(公告)号：US20210212933A1
公开(公告)日：2021-07-15
申请号：US17147556
申请日：2021-01-13
IPC分类号： A61K9/00 , A61K9/107 , A61K47/14 , A61M5/24 , A61K31/5377
摘要： The present invention provides an emulsion composition comprising aprepitant for treatment of emesis. Particularly, the invention is a ready-to-use emulsion compositions comprising aprepitant and medium chain triglycerides for administration by intravenous infusion, wherein the emulsion composition is also free of ethanol. Further, the invention also provides processes of preparing such compositions and their use for the prevention and control of acute and delayed chemotherapy-induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.
-
公开(公告)号：US20210177780A1
公开(公告)日：2021-06-17
申请号：US17115001
申请日：2020-12-08
IPC分类号： A61K31/165 , A61K47/18 , A61K47/26 , A61K47/44 , A61K47/12 , A61K47/02 , A61K9/08 , A61K9/00
摘要： The present invention relates to an ophthalmic composition comprising from 0.005% to 0.02% bimatoprost by weight and one or more pharmaceutically acceptable excipient, wherein said composition is free of benzalkonium chloride. The invention also relates to bimatoprost ophthalmic compositions comprising one or more penetration enhancers other than benzalkonium chloride. Further, the invention also provides a process of preparing such compositions and their use for lowering intraocular pressure and treating glaucoma.
-
34.发明授权公开(公告)号：US12029729B2
公开(公告)日：2024-07-09
申请号：US17871925
申请日：2022-07-23
发明人： Mandar V. Shah , Kumaresan Parthasarathi , Ilango Subramanian , Veerappan Subramanian , Aman Trehan
IPC分类号： A61K31/407 , A61K9/00 , A61K9/08 , A61K31/137 , A61K47/02 , A61K47/18
CPC分类号： A61K31/407 , A61K9/0048 , A61K9/08 , A61K31/137 , A61K47/02 , A61K47/183
摘要： This invention provides novel compositions comprising an anti-inflammatory agent and a mydriatic agent suitable for intraocular use, particularly ketorolac or pharmaceutically salts thereof and phenylephrine or pharmaceutically salts thereof, which are free of any buffering agent and yet, surprisingly, maintain stability for significant periods of time (e.g., at least about 3 months). The present invention also relates to a process of preparing such compositions and use thereof, e.g., in combination with intraocular ophthalmologic irrigation solutions.
-
公开(公告)号：US20240197675A1
公开(公告)日：2024-06-20
申请号：US18587694
申请日：2024-02-26
IPC分类号： A61K31/375 , A61K9/00 , A61K9/08 , A61K47/02 , A61K47/18
CPC分类号： A61K31/375 , A61K9/0019 , A61K9/08 , A61K47/02 , A61K47/183
摘要： The invention described here provides ready-to-use (RTU) pharmaceutical compositions in single unit dose packaging, such compositions including ascorbic acid compound(s), such as sodium ascorbate, and one or more pharmaceutically acceptable excipients (e.g., a carrier and optionally other agents, such as a tonicity agent, a chelator, or both). The compositions provided by the invention are stable when stored at 20° C. to 25° C.±2° C. for at least about 3 months. Compositions provided by the invention comprise an osmolality of between about 270 mOsm/kg to about 340 mOsm/kg and do not require dilution or further manipulation prior to use. In certain aspects, the invention comprises methods of using such compositions in the treatment of diseases, conditions, or symptoms related to vitamin C deficiency, such as, in specific embodiments, scurvy.
-
公开(公告)号：US11793789B2
公开(公告)日：2023-10-24
申请号：US17871924
申请日：2022-07-23
发明人： Mandar V. Shah , Kumaresan Parthasarathi , Ilango Subramanian , Veerappan Subramanian , Aman Trehan
IPC分类号： A61K31/407 , A61K9/00 , A61K31/137 , A61K47/02
CPC分类号： A61K31/407 , A61K9/0048 , A61K31/137 , A61K47/02
摘要： This invention provides novel compositions comprising an anti-inflammatory agent and a mydriatic agent suitable for intraocular use, particularly ketorolac or pharmaceutically salts thereof and phenylephrine or pharmaceutically salts thereof, which are free of any buffering agent and yet, surprisingly, maintain stability for significant periods of time (e.g., at least about 3 months). The present invention also relates to a process of preparing such compositions and use thereof, e.g., in combination with intraocular ophthalmologic irrigation solutions.
-
37.发明公开公开(公告)号：US20230270671A1
公开(公告)日：2023-08-31
申请号：US18154470
申请日：2023-01-13
IPC分类号： A61K9/08 , A61K31/4178 , A61K47/18 , A61K47/26
CPC分类号： A61K9/08 , A61K31/4178 , A61K47/26 , A61K47/186
摘要： The described invention provides, among other things, stable, ophthalmologically pilocarpine compounds characterized by markedly reduced buffer content and reduced buffering capacity as compared to previously developed or described pilocarpine compositions. In aspects, compositions provided by the invention comprise an effective amount of a uniform buffer component, wherein the pilocarpine compound and the uniform buffer component are present in amounts such that the concentration of pilocarpine in the compositions is remarkably higher than that the concentration of the uniform buffer component, particularly as compared against previously developed or described pilocarpine compositions. Such compositions surprisingly demonstrate pharmaceutically acceptable stability and, in aspects, stability equal to or statistically significantly greater than that of one or more previously developed or described reference product(s), while remaining suitable for use in treatment of ocular diseases. Further, the invention provides methods of manufacturing such or similar compositions and methods of use thereof.
-
38.发明公开公开(公告)号：US20230248701A1
公开(公告)日：2023-08-10
申请号：US18167059
申请日：2023-02-09
IPC分类号： A61K31/4178 , A61K31/498 , A61K47/44 , A61K47/26 , A61K31/14 , A61K9/00
CPC分类号： A61K31/4178 , A61K31/498 , A61K47/44 , A61K47/26 , A61K31/14 , A61K9/0048
摘要： The present invention provides, stable, pharmaceutically acceptable and ophthalmologically suitable gel compositions comprising therapeutically effective amounts of both a pilocarpine compound and a brimonidine compound and effective amount(s) of at least one polyethoxylated castor oil, which in aspects is/are present in a defined ratio with one or more active pharmaceutical ingredients. In aspects, such compositions are formulated as gel compositions. In certain embodiments, provided compositions are free of both a borate buffer and a citrate buffer. Compositions provided by the invention demonstrate stability, e.g., pH and active pharmaceutical ingredient stability, when stored under controlled room temperature conditions for an extended period of time. Further, the invention provides methods of manufacturing such compositions and methods of their use in treating ocular conditions, such as presbyopia.
-
公开(公告)号：US20230248700A1
公开(公告)日：2023-08-10
申请号：US18167057
申请日：2023-02-09
IPC分类号： A61K31/4178 , A61K31/498 , A61K9/00 , A61K47/02 , A61K31/14
CPC分类号： A61K31/4178 , A61K31/498 , A61K9/0048 , A61K47/02 , A61K31/14
摘要： The present invention provides relatively low pH, stable, pharmaceutically acceptable and ophthalmologically suitable compositions comprising effective amounts of pilocarpine and brimonidine compounds for treating an ocular condition, wherein compositions demonstrate a significant difference in the amount or rate of one or more pharmaceutical ingredient(s) absorbed or retained by ocular tissue or compared to reference composition(s) with similar compositional characteristics but having a significantly higher pH. In aspects compositions are characterizable by other elements, e.g., the inclusion of benzalkonium chloride, a limited amount of sodium chloride, or both. In embodiments, compositions are free of both a borate and a citrate buffer. Compositions provided by the invention surprisingly demonstrate pharmaceutically acceptable stability when stored under controlled room temperature conditions for an extended period of time. Further, the invention provides methods of manufacturing such compositions in liquid (solution) and gel forms, and methods of their use in treating conditions such as presbyopia.
-
公开(公告)号：US20230181525A1
公开(公告)日：2023-06-15
申请号：US18064204
申请日：2022-12-09
CPC分类号： A61K31/375 , A61K47/26 , A61K47/02 , A61K9/0019 , A61K9/08 , A61K47/183
摘要： The invention described here provides ready-to-use (RTU) pharmaceutical compositions in single unit dose packaging, such compositions including ascorbic acid compound(s), such as sodium ascorbate, and one or more pharmaceutically acceptable excipients (e.g., a carrier and optionally other agents, such as a tonicity agent, a chelator, or both). The compositions provided by the invention are stable when stored at 20° C. to 25° C.±2° C. for at least about 3 months. Compositions provided by the invention comprise an osmolality of between about 270 mOsm/kg to about 340 mOsm/kg and do not require dilution or further manipulation prior to use. In certain aspects, the invention comprises methods of using such compositions in the treatment of diseases, conditions, or symptoms related to vitamin C deficiency, such as, in specific embodiments, scurvy.
-
-
-
-
-
-
-
-
-
搜索结果
89 条记录 (耗时 0.022 秒)
